Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: A multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

Blood

Volumn 117, Issue 23, 2011, Pages 6109-6119

  Sutton, Laurent ^a   Chevret, Sylvie ^b   Tournilhac, Olivier ^c   Diviné, Marine ^d   Leblond, Véronique ^e   Corront, Bernadette ^f   Leprêtre, Stéphane ^g   Eghbali, Houchingue ^h   Van Den Neste, Eric ⁱ   Michallet, Mauricette ^j   Maloisel, Frédéric ^k   Bouabdallah, Krimo ^l   Decaudin, Didier ^m   Berthou, Christian ⁿ   Brice, Pauline ^b   Gonzalez, Hugo ^o   Chapiro, Elise ^e   Radford Weiss, Isabelle ^p   Leporrier, Nathalie ^q   Maloum, Karim ^e   Nguyen Khac, Florence ^e   Davi, Frédéric ^e   Lejeune, Julie ^b   Merle Béral, Hélène ^e   Leporrier, Michel ^q   more..

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Centre Hospitalier de la Region d'Annecy   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j UNIVERSITÉ DE LYON   (France)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m INSTITUT CURIE   (France)

ⁿ UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^o Centre hospitalier de Pontoise   (France)

^p HÔPITAL NECKER ENFANTS MALADES   (France)

^q CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; PREDNISONE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APLASIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HAZARD RATIO; HEMOLYTIC ANEMIA; HUMAN; IMMUNE THROMBOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RICHTER LYMPHOMA; SIDE EFFECT; SOLID TUMOR; TREATMENT RESPONSE; VIRUS INFECTION;

EID: 79959485796     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-317073     Document Type: Article

References (53)

1. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica. 2009; 94(9):1259-1265.
2. Byrd JC, Stilgenbauer S, and Flin IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2004;163-183.
3. Gribben JG. How I treat CLL up-front. Blood. 2010;115(2):187-197.
4. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
5. Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood. 1991;78(6): 1545-1551.
6. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044-2050.
7. Klepfish A, Rachmilewitz EA, Sarid M, Schattner A. Evaluating the impact of age and disease on survival of chronic lymphocytic leukaemia patients by a new method. Int J Clin Pract. 2009; 63(11):1601-1603.
8. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999;94(2):448-454. (Pubitemid 29323859)
9. Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-1757.
10. Leporrier M, Chevret S, Cazin B, et al. Randomised comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98(8):2319-2325.
11. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet. 2007;370(9583):230-239. (Pubitemid 47069536)
12. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107(3):885-891. (Pubitemid 43156283)
13. Byrd J-C, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6-14. (Pubitemid 36025880)
14. Hallek M, Fisher K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised open label phase 3 trial. Lancet. 2010;376(9747):1164-1174.
15. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971-2979. (Pubitemid 46224116)
16. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82(4): 1366-1376. (Pubitemid 23254015)
17. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994;12(4):748-758. (Pubitemid 24110914)
18. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia. 1998;12(11): 1699-1707. (Pubitemid 28502488)
19. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106(13):4389-4396. (Pubitemid 41775953)
20. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101(5):2049-2053. (Pubitemid 36237613)
21. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105(1):397-404. (Pubitemid 40053111)
22. Press OW, Livingston R, Mortimer J, et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol. 1991;9(3):423-431.
23. Michallet M, Dreger P, Sutton L, et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011;117(5):1516-1521.
24. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
25. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997;108(4):378-382. (Pubitemid 27411287)
26. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. (Pubitemid 32064784)
27. Damle RN, Wasil T, Fais F, et al. Ig V Gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
28. Maloum K, Sutton L, Baudet S, et al. Novel flowcytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol. 2002;119(4):970-975. (Pubitemid 35463821)
29. Grambsch P, Therneau T. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
30. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41(2):361-372.
31. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non Hodgkin's lymphoma. New Engl J Med. 1987;316(24):1493-1498. (Pubitemid 17076232)
32. Freedman AS, Ritz J, Neuberg D, et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991;77(11):2524-2529.
33. Williams CD, Harrison CN, Lister TA, et al. Highdose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol. 2001;19(3):727-735. (Pubitemid 32119087)
34. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 2004;103(7): 2850-2858. (Pubitemid 38393051)
35. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
36. Oudat R, Keating MJ, Lerner S, O'Brien S, Albitar M. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia. 2002;16(4):632-635. (Pubitemid 34449744)
37. Esteve J, Villamor N, Colomer D, Montserrat E. Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia [Letter]. Blood. 2002;99(5):1873-1874. (Pubitemid 34533068)
38. Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107(11):4563-4569. (Pubitemid 43801386)
39. Dreger P, Ritgen M, Böttcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia. 2005;19(7):1135-1138. (Pubitemid 40945994)
40. Maloum K, Sutton L, Le Garff-Tavernier M, et al. Evaluation of minimal residual disease in blood and bone marrow for chronic lymphocytic leukemia as assessed by 6-color flow cytometry [abstract]. Blood. 2006;108(11):2793.
41. Laszlo D, Galieni P, Raspadori D, et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cells collection in low grade non Hodgkin lymphoma patients. Leuk Lymphoma. 2000;37(1-2):157-161. (Pubitemid 30142590)
42. Tournilhac O, Cazin B, Leprètre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004;103(1):363-365. (Pubitemid 38029961)
43. Montillo M, Tedeschi A, Rossi V, et al. Successful CD34+ cell mobilization by intermediate dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia. 2004;18(1):57-62. (Pubitemid 38159439)
44. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
45. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103(9):3278-3281. (Pubitemid 38525651)
46. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12-17. (Pubitemid 44921829)
47. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective european group for blood and marrow transplantation analysis. J Clin Oncol. 2008; 26(31):5094-5100.
48. Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2009;15(1 suppl):53-58.
49. Dreger P, Döhner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438-2447.
50. Milligan DW, Kochethu G, Dearden C, et al. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol. 2006;133(2): 173-175.
51. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010; 24(12):2056-2062.
52. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with auto-transplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614-3620.
53. Flinn IW, Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant. 2001;27(6): 565-569. (Pubitemid 32401451)